Expertise in
3
conditions

Dr. Joel Neutel

Legal Medicine
Memorial Research Medical Clinic
14351 Myford Rd Ste B, 
Tustin, CA 
Expertise in
3
conditions
Memorial Research Medical Clinic
14351 Myford Rd Ste B, 
Tustin, CA 

Overview

Joel Neutel is a primary care provider, practicing in Legal Medicine in Tustin, California. Dr. Neutel is highly rated in 3 conditions, according to our data. His top areas of expertise are Hypertension, Type 2 Diabetes (T2D), Low Blood Sugar, and Obesity.

His clinical research consists of co-authoring 82 peer reviewed articles and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Legal Medicine

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

Memorial Research Medical Clinic
14351 Myford Rd Ste B, Tustin, CA 92780

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
A Single-Ascending and Repeated Subcutaneous Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Who Have the PNPLA3 I148M Genotype
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function
Enrollment Status: Completed
Publish Date: May 30, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
A Multi-Center, Randomized, Double-Blind, Placebo-controlled Proof-of-Activity Study With Orticumab in Subjects With Moderate-to-Severe Psoriasis and Cardiometabolic Risk Factors
Enrollment Status: Completed
Publish Date: February 02, 2024
Intervention Type: Drug
Study Drug: Orticumab
Study Phase: Phase 2
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
A Single Dose Pharmacokinetic Study of Tirzepatide in Subjects With Varying Degrees of Hepatic Impairment
Enrollment Status: Completed
Publish Date: March 24, 2023
Intervention Type: Drug
Study Phase: Phase 1
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Pharmacokinetics of Tirzepatide Following Administration to Subjects With Impaired Renal Function
Enrollment Status: Completed
Publish Date: March 23, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
A Phase 1 Study To Assess The Effect Of Moderate Renal Impairment On The Pharmacokinetics Of Surufatinib
Enrollment Status: Completed
Publish Date: November 03, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
A Phase 1 Study To Assess The Effect Of Hepatic Impairment On The Pharmacokinetics Of Surufatinib
Enrollment Status: Completed
Publish Date: August 30, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
A Phase I, Single-dose, Parallel Group Study to Assess the Pharmacokinetics of Olorofim in Subjects With Hepatic Impairment
Enrollment Status: Completed
Publish Date: March 16, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea
A Phase 4 Open Label Study to Assess the Safety and Effects of Crofelemer on the Gut Microbiome in Healthy Volunteers and in People Living With HIV/AIDS (PLWHA) With Non-Infectious Diarrhea
Enrollment Status: Completed
Publish Date: October 22, 2021
Intervention Type: Drug
Study Drug: Crofelemer delayed-release tablets
Study Phase: Phase 4
A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs
A Randomized, Double-blind, Parallel, Vehicle Controlled, Repeat Dose Comparative Phase 1b Study to Evaluate the Safety, Tolerability and Pharmacokinetics of ORTD-1 in Rheumatoid Arthritis Patients With Mild Disease Managed With DMARDs
Enrollment Status: Completed
Publish Date: October 19, 2021
Intervention Type: Drug
Study Drug: ORTD-1
Study Phase: Phase 1
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Safety and Efficacy of Cortexolone 17α-Propionate (CB-03-01) Cream, 1% Applied Twice Daily for 12 Weeks in Subjects With Facial Acne Vulgaris
Enrollment Status: Completed
Publish Date: November 20, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
An Open-label, Non-randomized, Single-dose, Parallel-group, Safety, Tolerability, and Pharmacokinetic Study of Tucatinib Administered at 300 mg in Fasted, Hepatically-impaired Male and Female Subjects and Fasted Matched-control Healthy Subjects
Enrollment Status: Completed
Publish Date: May 20, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
A Double-Blind, Randomized, Placebo-Controlled Dose-Ranging Study Evaluating the Efficacy and Safety of Once Weekly High Dose Oral Finasteride in the Treatment of Severe Nodulocystic Acne
Enrollment Status: Completed
Publish Date: February 15, 2019
Intervention Type: Drug
Study Phase: Phase 2
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Pharmacokinetics of LY3314814 in Subjects With Hepatic Impairment
Enrollment Status: Withdrawn
Publish Date: June 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 13 Less Clinical Trials

82 Total Publications

Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study.
Journal: Obesity (Silver Spring, Md.)
Published: July 25, 2025
Similar Doctors
Expertise in
1
conditions
Dr. Emmanuel Devera
Legal Medicine
Expertise in
1
conditions
Dr. Emmanuel Devera
Legal Medicine

George M. Jayatilaka MD Inc.

1045 Atlantic Ave Ste 818, 
Long Beach, CA 
 (22.4 miles away)
562-436-8117
Languages Spoken:
English
See accepted insurances

Emmanuel Devera is a primary care provider, practicing in Legal Medicine in Long Beach, California. Dr. Devera is highly rated in 1 condition, according to our data. His top areas of expertise are Gastritis, Chronic Erosive Gastritis, High Cholesterol, and Glucocorticoid-Remediable Aldosteronism.

Frequently Asked Questions about Dr. Joel Neutel

How do I make an appointment with Dr. Joel Neutel?

You can book an appointment with Dr. Joel Neutel by calling their office at 714-550-9990. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Joel Neutel a top-rated expert for Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Joel Neutel is classified as an Advanced expert for Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Joel Neutel specialize in?

While Dr. Joel Neutel is a Legal Medicine, they have specific expertise in Hypertension, Type 2 Diabetes (T2D), and Low Blood Sugar. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Legal Medicine.

Does Dr. Joel Neutel participate in research or clinical trials?

Yes. Dr. Joel Neutel has published 82 articles and abstracts on conditions like Hypertension. You can view a list of Dr. Joel Neutel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Joel Neutel accept my insurance?

Dr. Joel Neutel accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 714-550-9990 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Neutel's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile